CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...

According to the terms of the deal, Blackstone will acquire a 60 percent stake while CMIC HD will retain the remaining 40 percent stake in the company.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC ...

Patrick Tan’s project in Singapore will create Asia’s first functional precision medicine system with the potential to fine-tune treatments and drug responses for Asians.

A decade after scientists in The Picower Institute for Learning and Memory at MIT first began testing whether sensory stimulation of the brain's 40Hz "gamma" frequency rhythms could treat Alzheimer's ...

Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as ...